on PHAXIAM THERAPEUTICS (isin : FR001400K4B1)
PHAXIAM Therapeutics suspends trading of its shares
On June 18, 2025, PHAXIAM Therapeutics, a biopharmaceutical company specializing in treatments for resistant bacterial infections, announced the suspension of trading of its shares on Euronext Paris. The suspension will take effect before the opening of the stock market and will last until the definitive delisting of its shares.
The company has requested this suspension from Euronext, and no compensation or reimbursement will be offered to shareholders. This procedure follows a previously announced decision. PHAXIAM remains committed to developing innovative treatments using phages to target resistant bacteria such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all PHAXIAM THERAPEUTICS news